Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CXL-1427 Ascending Dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CXL-1427 (BMS-986231) | EXPERIMENTAL | Experimental |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| CXL-1427 Ascending Dose | DRUG | - |
| Placebo | OTHER | - |
| CXL-1427 Descending Dose | DRUG | - |
Inclusion Criteria: * No evidence of any acute or chronic health disorder * Not have taken any prescription medication within 15 days of study entry * Not have taken any over-the-counter medication or herbal/vitamin supplement within 3 days of study entry * Not have not have any dietary restriction...
Top 20 of 31 competitors
CXL-1427 is an investigational small molecule being studied for the treatment of Heart Failure. It is administered as a single continuous intravenous (IV) infusion for up to 48 hours. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
CXL-1427 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety of this investigational drug for Heart Failure.
CXL-1427 is in Phase 1 clinical development. A first-in-human study of the drug has been completed, evaluating the safety of single continuous intravenous infusions for up to 48 hours in healthy volunteers. The drug remains investigational and is not yet approved.
CXL-1427 has one completed Phase 1 clinical trial registered as NCT02819271. This first-in-human study assessed the safety of single continuous intravenous infusions of CXL-1427 for up to 48 hours in 80 healthy volunteers, with a placebo-controlled, randomized, double-blind design.
CXL-1427 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Heart Failure. The completed clinical trial focused on safety in healthy volunteers, and the drug has not yet progressed to later-stage studies or regulatory approval.